Sentence examples for mutant plasmids using from inspiring English sources

COS-1 cells were electroporated with WT pVAXD2i and mutant plasmids using the protocol described in [64].

MCF-7 cells were separately transfected with various caspase-3 mutant plasmids using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the provided protocol.

To establish ebp1-overexpressing stable transfectants, subconfluent MCF-7 cells in 100-mm tissue culture dishes were transfected with 10  μg of GFP-tagged wild-type ebp1 or the T261 mutant plasmids using Fugene-6 according to the manufacturer's protocol.

BPAEC cells were transfected with pCMV-myc ezrin, pCMV-myc radixin, pCMV-myc moesin or pCMV-HA NHERF2 wild type and mutant plasmids using Lipofectamine 2000 transfection reagents (Invitrogen Corporation, Carlsbad, CA), according to the manufacturer's instructions.

RAW 264.7 cells (5 × 106 cells) were plated in 24-well plates and transiently transfected with pNF-κB-Luc plasmid (5 × NF-κB; Stratagene, La Jolla, CA, USA) or iNOS-luciferase reporter plasmid [ 37] or p50 (C62S) mutant plasmids using a mixture of plasmid and lipofectAMINE PLUS in OPTI-MEN according to manufacturer's specification (Invitrogen, Carlsbad, CA, USA).

The dna2Δ pGALΔ mre11-H125N (pGAL::DNA2) was transformed with the same set of Dna2 mutant plasmids used in Figure 6, to yield double transformants, dna2Δ pGALΔ mre11-H125N (pGAL::DNA2) pRS414-dna22 mutant).

TEFs were transfected with mutant RCAS.linker.Δ3'PBS plasmids using the Lipofectamine PLUS reagent, as described by Invitrogen.

Cells were transiently transfected by WT and mutant CFTR plasmids using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions.

A total of 1 × 10 SK-N-SH cells were transfected with 2  μg of FUS/TLS, FUS/TLS R521C mutant and LDLR plasmids using the Amaxa-Nucleofector-System (Lonza, Allendale, NJ, USA) according to the manufacturer's instructions.

hPXR full-length plasmid was used as a wild-type template to generate a series of mutant plasmids by using the QuikChange II Site-Directed Mutagenesis Kit (Agilent, Santa Clara, CA) according to the manufacturer-supplied protocol.

Cos7 cells were transiently co-transfected with 5 µg of WT or mutant CAT-3 expression plasmids using a neon electroporation system (Invitrogen).